Design of pH-independent extended release matrix tablets of minocycline hydrochloride for the treatment of dementia

Archives of Pharmacal Research

Volumn 32, Issue 11, 2009, Pages 1593-1598

  Cha, Kwang Ho ^a   Park, Junsung ^a   Cho, Wonkyung ^a   Gu, Dong Geon ^a   Jeong, Kihyang ^a   Hwang, Sung Joo ^a  

^a Chungnam National University   (South Korea)

Author keywords

Eudragit; Matrix tablet; Minocycline HCl; PH independent

Indexed keywords

EUDRAGIT; FUMARIC ACID; LUBRICATING AGENT; MACROGOL; MAGNESIUM STEARATE; MINOCYCLINE; STEARIC ACID;

ARTICLE; CONTROLLED STUDY; DEMENTIA; DRUG DESIGN; DRUG FORMULATION; DRUG GRANULATION; DRUG RELEASE; MATRIX TABLET; PH;

ANIMALS; ANTI-BACTERIAL AGENTS; DELAYED-ACTION PREPARATIONS; DEMENTIA; EXCIPIENTS; FUMARATES; HUMANS; HYDROGEN-ION CONCENTRATION; LUBRICANTS; MINOCYCLINE; POLYETHYLENE GLYCOLS; POLYMETHACRYLIC ACIDS; TABLETS;

EID: 72049100389     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-009-2112-2     Document Type: Article

References (20)

1. C. Barcia A. Fernandez-Barreiro M. Poza M. T. Herrero 2003 Parkinson's disease and inflammatory changes Neurotox. Res. 5 411 418 10.1007/BF03033170 14715444
2. G. Berthon M. Brion L. Lambs 1983 Metal ion-tetracycline interactions in biological fluids. 2. potentiometric study of magnesium complexes with tetracycline, oxytetracycline, doxycycline, and minocycline, and discussion of their possible influence on the bioavailability of these antibiotics in blood plasma J. Inorg. Biochem. 19 1 18 10.1016/0162-0134(83)85009-0 1:CAS:528:DyaL3sXkvFykurk%3D 6619838
3. M. Chen V. O. L. Ona M. Li R. J. Ferrante K. B. Fink S. Zhu J. Bian L. Guo L. A. Farrell S. M. Hersch W. Hobbs J. P. Vonsattel J. H. Cha R. M. Friedlander 2000 Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington's disease Nat. Med. 6 797 801 10.1038/80538 1:CAS:528:DC%2BD3cXltValtLs%3D 10888929 (Pubitemid 30792201)
4. T. M. Dawson V. L. Dawson 2003 Molecular pathways of neurodegeneration in Parkinson's disease Science 302 819 822 10.1126/science.1087753 1:CAS:528:DC%2BD3sXos1Cmt7w%3D 14593166 (Pubitemid 37339614)
5. Desjardins, A. and Bolduc, B., Controlled-Release Oral Dosage Form. Patent US 20080318910 (2008).
6. Y. Du Z. Ma S. Lin R. C. Dodel F. Gao K. R. Bales L. C. Triarhou E. Chernet K. W. Perry D. L. G. Nelson S. Luecke L. A. Phebus F. P. Bymaster S. M. Paul 2001 Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease Proc. Natl. Acad. Sci. USA 98 14669 14674 10.1073/pnas.251341998 1:CAS:528:DC%2BD3MXptFCksbo%3D 11724929 (Pubitemid 33121449)
7. P. S. Hiremath R. N. Saha 2008 Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: Design and in vitro evaluations Int. J. Pharm. 362 118 125 10.1016/j.ijpharm.2008.06.019 1:CAS:528:DC%2BD1cXhtVGjs7fN 18640251
8. H. Y. Kim Y. H. Suh 2009 Minocycline and neurodegenerative diseases Behav. Brain Res. 196 168 179 10.1016/j.bbr.2008.09.040 1:CAS:528: DC%2BD1cXhsFaht7%2FE 18977395
9. R. W. Korsmeyer R. Gurny E. M. Doelker P. Buri N. A. Peppas 1983 Mechanism of solute release from porous hydrophilic polymers Int. J. Pharm. 15 25 35 10.1016/0378-5173(83)90064-9 1:CAS:528:DyaL3sXksVens7Y%3D
10. M. Marvola P. Nykäen S. Rautio N. Isonen A. M. Autere 1999 Enteric polymers as binders and coating materials in multiple-unit site-specific drug delivery systems Eur. J. Pharm. Sci. 7 259 267 10.1016/S0928-0987(98)00032-3 1:CAS:528:DyaK1cXnvVSrt7s%3D 9845814 (Pubitemid 29015744)
11. J. W. Moore H. H. Flanner 1996 Mathematical comparison of dissolution profiles Pharm. Technol. 20 60 74
12. Oren, P. L., and Seidler, W. M. K., Sustained release matrix. Patent US 4968508 (1990).
13. M. N. Pékli M. E. H. Mesbah G. Peth 1996 Equilibrium studies on tetracycline-metal ion systems J. Pharm. Biomed. Anal. 14 1025 1029 10.1016/S0731-7085(96)01734-7 (Pubitemid 26235152)
14. S. Rizk J. C. Guyot C. Duru D. Gaudy 1995 Influence of lubricant properties on compression behaviour and drug dissolution rate of scleroglucan hydrophilic matrix Int. J. Pharm. 126 57 63 10.1016/0378-5173(95)04084-6 1:CAS:528:DyaK28XksVSrsw%3D%3D (Pubitemid 26018572)
15. A. Streubel J. Siepmann A. Dashevsky R. Bodmeier 2000 pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets J. Controlled Release 67 101 110 10.1016/S0168-3659(00)00200-5 1:CAS:528:DC%2BD3cXisV2nt7w%3D (Pubitemid 30201685)
16. S. Takka S. Rajbhandari A. Sakr 2001 Effect of anionic polymers on the release of propranolol HCl from matrix tablets Eur. J. Pharm. Biopharm. 52 75 82 10.1016/S0939-6411(01)00147-3 1:CAS:528:DC%2BD3MXkvVeksLY%3D 11438426 (Pubitemid 32594790)
17. P. Timmins A. M. Delargy J. R. Howard 1997 Optimization and characterization of a pH-dependent extended-release hydrophilic matrix tablet Pharm. Dev. Technol. 2 25 31 10.3109/10837459709022606 1:CAS:528: DyaK2sXhsl2ltL0%3D 9552428
18. K. Thoma T. Zimmer 1990 Retardation of weakly basic drugs with diffusion tablets Int. J. Pharm. 58 197 202 10.1016/0378-5173(90)90195-A 1:CAS:528:DyaK3cXhvVGlurk%3D (Pubitemid 20079733)
19. M. V. S. Varma A. M. Kaushal S. Garg 2005 Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices J. Controlled Release 103 499 510 10.1016/j.jconrel.2004.12.015 1:CAS:528:DC%2BD2MXitV2htro%3D (Pubitemid 40342544)
20. C. L. Zuch V. K. Nordstroem L. A. Briedrick G. R. Hoernig A. C. Granholm P. C. Bickford 2000 Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion J. Comp. Neurol. 427 440 454 10.1002/1096-9861(20001120)427:3<440::AID-CNE10>3.0.CO;2-7 1:STN:280:DC%2BD3M%2FmvV2ksA%3D%3D 11054705 (Pubitemid 30803476)